Crystagen from Super Human Peptides UK is a highly targeted, synthetic tripeptide (sequence: Glu-Asp-Pro). It is part of the advanced class of short peptide bioregulators engineered by the St. Petersburg Institute of Bioregulation and Gerontology.
In laboratory research, Crystagen serves as a premier model for investigating the reversal of immune senescence (aging of the immune system) and the restoration of thymic function. Researchers utilize this peptide because it acts as an epigenetic switch specifically for the thymus gland. By entering the nucleus of thymic cells and interacting directly with the DNA, Crystagen stimulates the normalization of T-lymphocyte production and maturation.
Produced under GMP-compliant conditions and verified for 99% purity or higher, Crystagen is an essential tool for advanced in-vitro and in-vivo research into immunodeficiency, post-infection recovery, and the foundational mechanisms of aging.
- —Thymic Bioregulator: A short, 3-amino-acid peptide that acts as an epigenetic switch specifically for thymus tissue.
- —Immune Normalization: Acts to balance the immune system (lowering hyper-reactive states while boosting deficient ones) rather than strictly stimulating it.
- —T-Cell Maturation: Promotes the differentiation and maturation of T-lymphocytes (CD3, CD4, CD8).
- —Synthetic Analogue: Designed as a highly stable, short-chain synthetic alternative to complex, animal-derived thymic extracts.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Thymic Involution: Preclinical models investigating the regeneration of functional thymus tissue in aged subjects experiencing natural glandular atrophy.
- —Lymphocyte Populations: Measuring the dose-dependent restoration of optimal CD4/CD8 T-cell ratios following chemically induced immunosuppression.
- —Epigenetic Gene Silencing: Studying the intracellular signaling pathways that allow short peptides to bind to promoter regions of DNA and reactivate dormant immune-repair genes.
- —Autoimmune and Inflammatory Models: Evaluating the peptide's ability to restore immune tolerance and down-regulate chronic, systemic inflammation.
- —Viral and Bacterial Challenge: Researching the accelerated recovery and enhanced survival rates of animal models exposed to acute pathogenic stress following bioregulator administration.
Crystagen was developed through the pioneering research of Dr. Vladimir Khavinson. Khavinson's team identified that naturally occurring short peptides guide the development and function of nearly every organ system, but their production drops precipitously as an organism ages.
Laboratory studies utilizing Crystagen have demonstrated profound, tissue-specific immune recovery. In foundational preclinical studies, the application of Crystagen to immunodeficient animal models resulted in a rapid normalization of cell-mediated immunity, specifically elevating depressed T-cell counts. Furthermore, because Crystagen is an epigenetic regulator rather than a traditional drug, researchers note that it lacks the toxicity and receptor-desensitization issues common with other immune stimulants.
It effectively "reminds" aged thymic cells how to function properly, making it a cornerstone compound in the study of longevity and psychoneuroimmunology.
- 1.Khavinson, V.H. et al., "Peptide bioregulators: A new class of geroprotectors," Annals of the New York Academy of Sciences, 2002.
- 2.Kuznik, B.I. et al., "The effect of peptide bioregulators on the state of immunity and hemostasis," Advances in Gerontology, 2011.
- 3.Khavinson, V. et al., "Peptides promote longevity," Current Aging Science, 2013.
- 4.Lin'kova, N.S. et al., "Peptide regulation of the immune system functioning during aging," Advances in Gerontology, 2011.
